AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31985629
Drug: No sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sequential compression devices
Trial: 30365588
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg SC twice weekly for 12 weeks, then 50 mg SC once weekly for an additional 12 weeks
Trial: 21865366
Drug: L-T(3)
RxNorm normalized name: (T,G)-A-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T(3)
Trial: 21865366
Drug: L-T(4)
RxNorm normalized name: (T,G)-A-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T(4)
Trial: 16932963
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ICS plus long-acting beta2 agonist)
Trial: 11524643
Drug: Platelet glycoprotein
RxNorm normalized name: PLATELET GLYCOPROTEIN VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet glycoprotein IIb/IIIa inhibitors (various studies)
Trial: 11524643
Drug: Tirofiban plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban plus heparin (PRISM-PLUS study)
Trial: 11524643
Drug: Integrilin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrilin therapy (PURSUIT trial)
Trial: 11524643
Drug: Least harmful
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Least harmful treatment arm (GUSTO‐IV trial)
Trial: 9458423
Drug: Linsidomine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linsidomine (1 mg.h‐1 on average)
Trial: 9458423
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (2.5 mg.h‐1 on average)
Trial: 2693029
Drug: control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: control solution (CS)
Trial: 16413056
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human interleukin 11 (rhIL-11) at 50 microg/kg/day and granulocyte-macrophage colony stimulating factor (GM-CSF) at 250 microg/kg/day administered from day 11 until recovery.
Trial: 16413056
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human interleukin 11 (rhIL-11) and GM-CSF as supportive care after chemotherapy.
Trial: 12831635
Drug: Insulin antibodies
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin antibodies levels after severe hypoglycemia
Trial: 12831635
Drug: Insulin antibodies
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin antibodies levels before severe hypoglycemia
Trial: 12831635
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group insulin antibodies levels
Trial: 8638169
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy at specific stages of progression of retinopathy
Trial: 1630657
Drug: Pyridostigmine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (30 mg orally, t.i.d. for 7 consecutive days)
Trial: 6149490
Drug: Bethanechol chloride
RxNorm normalized name: Bethanechol Chloride
DrugBank: Bethanechol (DB01019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bethanechol chloride infusion (0.05 to 0.7 mg/day)
Trial: 6149490
Drug: Single‐blind saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐blind saline placebo infusions
Trial: 17991659
Drug: Lycopene supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene supplementation (30 mg/d for 8 weeks)
Trial: 2109432
Drug: Lactinex (culture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactinex (culture of L. acidophilus and L. bulgaricus), administered four times a day for ten days
Trial: 2109432
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered four times a day for ten days
Trial: 11282447
Drug: Alcoholic drinks
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcoholic drinks (0.7 g/kg)
Trial: 9215018
Drug: Intraperitoneal lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal lignocaine (50 ml containing 200 mg lignocaine and 1:500,000 adrenaline)
Trial: 9215018
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (50 ml saline i.p.)
Trial: 8116338
Drug: Specific cognitive
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific cognitive treatment (20 pts) including direct training, compensatory strategies, and neuropsychotherapy
Trial: 8116338
Drug: Specific cognitive
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific cognitive treatment (20 pts)
Trial: 3547053
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of elemental zinc (as 220 mg zinc sulphate), three times a day for six weeks
Trial: 3547053
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of zinc a day
Trial: 28401310
Drug: Daily undulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily undulating periodised resistance training
Trial: 23751738
Drug: Endovascular aortic
RxNorm normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular aortic repair (EVAR); surgical success rate 100%, perioperative mortality rate 0.8%, mean operative duration 150 min, mean blood loss 140 ml, mean hospitalization time 15.5 days, mean hospitalization cost RMB 104,800; stent graft patency 96% (120 cases), 10 deaths, 8 complications (5.6%).
Trial: 23751738
Drug: Open surgery;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open surgery; surgical success rate 98.8%, perioperative mortality rate 2.3%, mean operative duration 230 min, mean blood loss 450 ml, mean hospitalization time 30 ± 3 days, mean hospitalization cost RMB 58,000; stent graft patency 98.8% (79 cases), 8 deaths (10%).
Trial: 20734238
Drug: Legume enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Legume enriched diet (1.5 servings/1,000 kcal), high fiber (21 g/1,000 kcal), low GI (GI = 38)
Trial: 20734238
Drug: Healthy American
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy American diet (no legume consumption, fiber consumption = 9 g/1,000 kcal, GI = 69)
Trial: 18565239
Drug: Solifenacin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (5 mg and 10 mg)
Trial: 18565239
Drug: Tolterodine (IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine (IR 2 mg bd/ER 4 mg)
Trial: 15972086
Drug: Zonisamide (540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (540 mg/day during maintenance phase)
Trial: 10505585
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg for 3 to 5 days
Trial: 10505585
Drug: Open-label olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label olanzapine (10-25 mg/day) for 9 weeks
Trial: 7006561
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by cyclophosphamide (100 mg/kg BW in daily intravenous doses of 200 mg)
Trial: 7006561
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy (about 5500 rad tumour dose by telecobalt) and surgery
Trial: 31819948
Drug: Radiotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy combined with chemotherapy and/or thermotherapy
Trial: 27352956
Drug: High onion
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High onion group (HO; n = 28) - 100 to 160 g/d of onion for 8 weeks
Trial: 27352956
Drug: Low onion
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low onion group (LO; n = 28) - 30 to 40 g/d small onions for 8 weeks
Trial: 17431101
Drug: Investigational agent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational agent (growth-inhibitory drug) during the run-in period, followed by randomization to continue or discontinue therapy.
Trial: 15173844
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Trial: 15173844
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Trial: 15173844
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Trial: 11224687
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Butyrates + Hydroxyurea)
Trial: 9138198
Drug: Group-based behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based behavior modification intervention consisting of 5 weekly, 90-min sessions including skill training, self-monitoring, weekly feedback, and group support
Trial: 2975091
Drug: Verapamil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (1 mg intracoronarily)
Trial: 29430970
Drug: Pain Exposure
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Exposure Physical Therapy (maximum of five sessions)
Trial: 29430970
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment conforming with the Dutch multidisciplinary guideline
Trial: 23941670
Drug: 2.5 g/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/kg/day of amino acids (standard AA [SAA] group)
Trial: 23941670
Drug: 4 g/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/kg/day of amino acids (high AA [HAA] group)
Trial: 23941670
Drug: 2.5 g/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/kg/day of amino acids (SAA group)
Trial: 23941670
Drug: 4 g/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/kg/day of amino acids (HAA group)
Trial: 21923847
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (long-acting analogue; LAA)
Trial: 21923847
Drug: 70% insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70% insulin aspart protamine and 30% insulin aspart (biphasic insulin analogue; BIA)
Trial: 21923847
Drug: Twice-daily BIA
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily BIA therapy
Trial: 19808287
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment and device-guided paced breathing (n=12)
Trial: 19808287
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (n=12)
Trial: 16478629
Drug: CIAIV‐CCRT (intraarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIAIV‐CCRT (intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil)
Trial: 16478629
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (radiation therapy alone)
Trial: 16845252
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg daily
Trial: 12882847
Drug: ACEI alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI alone (lisinopril/enalapril 40 mg daily or captopril 150 mg daily)
Trial: 28805468
Drug: Single-pill fixed-dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-pill fixed-dose combination therapy
Trial: 28805468
Drug: Two-pills combination
RxNorm normalized name: Two-Dyne Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-pills combination therapy
Trial: 23851000
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) (N=30)
Trial: 23851000
Drug: Child-Centered Therapy
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-Centered Therapy (CCT) (N=17)
Trial: 23851000
Drug: Pre-treatment encouragement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment encouragement of bravery
Trial: 21877998
Drug: DHEA 50
RxNorm normalized name: Natrol Mood & Stress DHEA 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 50 mg q.d. for 4 months
Trial: 19722442
Drug: Phosphoric acid
RxNorm normalized name: Phosphoric Acid
DrugBank: Phosphoric acid (DB09394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phosphoric acid and a single-bottle dentin bonding agent (Group 2)
Trial: 18086056
Drug: NASHA (Restylane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NASHA (Restylane and/or Perlane, mean dosage 69 mg)
Trial: 15263832
Drug: Adrenalin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenalin 0.1 mg with 10 ml 0.9% NaCl (1/100,000 dilution)
Trial: 15263832
Drug: Physiological serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological serum solution
Trial: 11427321
Drug: Intramuscular infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular infusion of 0.5 ml hypertonic saline (6%) into the tibialis anterior muscle
Trial: 3344411
Drug: APD 30
RxNorm normalized name: APD-209
DrugBank: APD-209 (DB18759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD 30 mg
Trial: 3344411
Drug: APD 45
RxNorm normalized name: APD-209
DrugBank: APD-209 (DB18759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD 45 mg
Trial: 3344411
Drug: APD 60
RxNorm normalized name: APD-209
DrugBank: APD-209 (DB18759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD 60 mg
Trial: 3344411
Drug: APD 90
RxNorm normalized name: APD-209
DrugBank: APD-209 (DB18759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD 90 mg
Trial: 3344411
Drug: APD (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD (all doses)
Trial: 22050797
Drug: Oral atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral atenolol 50 mg twice daily for one day prior to surgery (Group I)
Trial: 22050797
Drug: Intraoperative nitroprusside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative nitroprusside infusion (Group II)
Trial: 22050797
Drug: Intraoperative esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative esmolol infusion (Group III)
Trial: 18435833
Drug: Co-amoxiclav 375
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav 375 mg
Trial: 18435833
Drug: Antibiotics (general)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (general)
Trial: 17310784
Drug: Moxifloxacin (Avelox)
RxNorm normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (Avelox) 400 mg every 24 hours, first intravenously then orally, for a total treatment duration of 7 to 12 days (average 8.45 ± 1.53 days).
Trial: 17310784
Drug: Moxifloxacin treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin treatment.
Trial: 12932070
Drug: Atorvastatin (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (standard doses for at least 4 months)
Trial: 9120965
Drug: Intravesical morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical morphine 0.05 mg/ml
Trial: 9120965
Drug: Intravesical morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical morphine 0.375 mg/ml
Trial: 9120965
Drug: Intravesical morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical morphine 0.5 mg/ml
Trial: 9120965
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no morphine infusion)
Trial: 3531226
Drug: Inactivated trivalent
RxNorm normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated trivalent influenza virus vaccine (administered parenterally)
Trial: 22389254
Drug: Ofatumumab (CD20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (CD20 mAb; dose 1, 300 mg and doses 2-8, 500 or 1000 mg)
Trial: 15777291
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil (0.4 microg kg(‐1) PCA doses)
Trial: 15777291
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide (50% inhaled)
Trial: 7730723
Drug: Minocycline 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 200 mg daily
Trial: 7730723
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg daily
Trial: 7730723
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg daily (after 5 months of treatment)
Trial: 7730723
Drug: Minocycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (100 mg daily for 5 months)
Trial: 32941
Drug: Oral androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral androgen (27 patients)
Trial: 30501389
Drug: Manual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual physical therapy (3 sessions including desensitization maneuvers)
Trial: 21982052
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention including oral and written explanations about cardiac rehabilitation, a follow-up telephone call, and a seminar for medical staff.
Trial: 21982052
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care without additional treatment.
Trial: 17760243
Drug: Lornoxicam (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (16 mg IV before surgery, 8 mg at 12h and 24h postoperatively)
Trial: 17760243
Drug: Morphine with
RxNorm normalized name: opium alkaloids with morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine with PCA (Control Group M)
Trial: 10194739
Drug: Higher methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher methadone doses
Trial: 10194739
Drug: Lower methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower methadone doses
Trial: 2258583
Drug: Acipimox 500
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 500 mg
Trial: 6447999
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5-hydroxytryptophan and pyridoxine
Trial: 25709055
Drug: Enhanced Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Exercise Therapy
Trial: 21724950
Drug: Tablet form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet form II of semagacestat (140 mg)
Trial: 21724950
Drug: Semagacestat (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semagacestat (140 mg) administered fed or fasting
Trial: 21724950
Drug: Semagacestat (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semagacestat (140 mg) at different times of dosing (morning fasting, evening fasting)
Trial: 17222829
Drug: Unopposed conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unopposed conjugated estrogen therapy (0.625 mg/d)
Trial: 15703460
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) 50 mg intramuscularly twice weekly combined with erythropoietin (EPO) 1,000 U three times weekly
Trial: 15703460
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) 1,000 U three times weekly
Trial: 12127032
Drug: Continuous morphine
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine (CM) at 10 microg/kg/h intravenous infusion
Trial: 12127032
Drug: Intermittent morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent morphine (IM) at 30 microg/kg every 3 hours